Evidence map›Paper›PMID 42382942›Full record

ArticleMolecular therapy. Advances2026

Omics-guided engineering of CHO cells reveals host targets to support AAV production.

Konstantina Tzimou, Guillem López-García, Meryem Irem Sipahi, Lars K Nielsen, Jesús Lavado-García

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Konstantina TzimouThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Guillem López-GarcíaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Meryem Irem SipahiDTU Bioengineering, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Lars K NielsenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.
Jesús Lavado-GarcíaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs Lyngby, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scalable production of recombinant adeno-associated viruses (rAAVs) remains a critical challenge in gene therapy manufacturing. While HEK293 and insect cell systems dominate current production platforms, each presents significant limitations in cost, scalability, and product quality. Chinese hamster ovary (CHO) cells represent an attractive alternative given their established use in biopharmaceutical manufacturing, yet their inability to efficiently support rAAV assembly has hindered development of CHO-based rAAV bioprocesses. Here, we investigate the molecular basis of this limitation by expressing individual AAV and adenoviral helper proteins in CHO cells and characterizing their effects using integrated transcriptomic and proteomic analyses. Functional enrichment analyses revealed that mitochondrial biogenesis was broadly suppressed across conditions, accompanied by downregulation of antiviral nuclear regulation, signaling networks, including the JAK-STATand interferon-stimulated gene pathways. Functional evaluation of host proteins identified from the omics analyses showed that overexpression of nuclear components like Mx2 and Rad23A supported rAAV production, reaching a yield of 10

Indexed as

biomanufacturingcell platformCHO cellsgene therapynuclear regulationproteomicsrAAVrecombinant adeno-associated virustranscriptomicsviral vector

Identifiers

PMID42382942
PMCPMC13315805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.